Anti-Diabetes Drugs - Baltics | Statista Market Forecast

The Anti-Diabetes Drugs market in the Baltics is projected to achieve a revenue of US$58.48m in 2024.
It is expected to experience a steady annual growth rate (CAGR 2024-2029) of 7.56%, leading to a market volume of US$84.20m by 2029.
When compared globally, United States will generate the highest revenue, reaching US$37.84bn in 2024.
The demand for anti-diabetes drugs in the Baltics is on the rise due to the increasing prevalence of diabetes in the region.

Definition:
The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors. While patients with type 1 diabetes require lifelong insulin therapy, type 2 diabetes can also be treated with medication.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Novo Nordisk, Eli Lilly, Sanofi, Merck & Co

Drugs to treat diabetes mellitus (oral intake and injections)
Insulin
Non-insulinotropic anti-diabetic drugs

Drugs to treat other metabolic disorders or other autoimmune diseases
Lipid-lowering agents
Drugs to treat hypertension
Diagnostics
Devices such as continuous glucose monitors

The Anti-Diabetes Drugs market in Baltics has been steadily growing in recent years.

Customer preferences: There is a growing demand for anti-diabetes drugs in the Baltics due to the increasing prevalence of diabetes in the region. Patients are looking for effective drugs that can help them manage their condition and improve their quality of life. Additionally, there is a preference for drugs that have fewer side effects and are easier to administer.

Trends in the market: One of the major trends in the Anti-Diabetes Drugs market in Baltics is the increasing use of combination therapies. This involves using multiple drugs to achieve better glycemic control. Another trend is the growing popularity of GLP-1 receptor agonists, which are injectable drugs that stimulate insulin secretion and reduce blood glucose levels. These drugs are preferred by patients who have difficulty controlling their blood sugar levels with oral medications alone.

Local special circumstances: The Anti-Diabetes Drugs market in Baltics is also influenced by local factors such as the availability of healthcare services and the regulatory environment. The healthcare systems in the region are still developing, which means that access to healthcare services can be limited in some areas. Additionally, the regulatory environment can be complex and may affect the availability of certain drugs in the market.

Underlying macroeconomic factors: The Anti-Diabetes Drugs market in Baltics is also influenced by macroeconomic factors such as population growth, income levels, and healthcare spending. The population in the region is aging, which means that the prevalence of diabetes is likely to increase in the coming years. Additionally, rising income levels and healthcare spending are likely to drive demand for anti-diabetes drugs in the region. However, economic uncertainty and changes in healthcare policies could also affect the growth of the market in the future.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

In 2021, diabetes mellitus caused an estimated 1.62 million deaths worldwide, making it the eighth leading cause of death. Furthermore, it is estimated that 537 million people are currently living with diabetes around the world, with this number projected to rise to some 783 million by the year 2045. Diabetes describes a group of metabolic diseases which cause high blood sugar levels. There are three types of diabetes: type 1 diabetes, type 2 diabetes, and gestational diabetes. However, the majority of diabetes cases are type 2, with an estimated 90 to 95 percent of diabetes cases in the United States type 2. Risk factors for type 2 diabetes include being overweight, being physically inactive, being 45 and older, and having prediabetes.